Ligand Pharmaceuticals vs Organigram Global
LGND and OGI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGND and OGI compare
Organigram Global grew revenue faster over the last twelve months (77.8% versus 1.0% for Ligand Pharmaceuticals).
Ligand Pharmaceuticals scores higher on the StockData Score (6 against 4 for Organigram Global), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGND | OGI |
|---|---|---|
| Size and price | ||
| Market cap | $6.2B | – |
| Share price | $308.79 | $0.829 |
| Change, 1 year | 50.2% | −48.5% |
| Change, 5 years | 90.7% | −89.6% |
| Beta (5Y) | 1.30 | 1.51 |
| Employees | 47 | – |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 135× | – |
| P/S | 24.3× | – |
| P/B | 6.4× | – |
| EV/EBITDA | 113× | – |
| P/FCF | 68.2× | – |
| FCF yield | 1.5% | – |
| Fair value | $55.48 | – |
| Margin of safety | −457% | – |
| Growth | ||
| Revenue growth (TTM) | 1.0% | 77.8% (better) |
| Revenue growth, 5Y average | 10.4% | 83.6% (better) |
| Net income growth (TTM) | 5.9% | – |
| EPS growth (TTM) | 18.7% | – |
| Profitability | ||
| Gross margin | – | 34.8% |
| Operating margin | 10.1% (better) | −5.9% |
| Net margin | 20.3% | – |
| FCF margin | 35.7% (better) | −9.5% |
| Return on equity | 5.4% | – |
| Return on invested capital | 2.6% | – |
| Financial health | ||
| Debt / equity | 1.17 | – |
| Net debt / EBITDA | 11.26 (better) | −31.24 |
| Interest coverage | 3.1× | – |
| Current ratio | 1.22 | 2.26 (better) |
| Altman Z-score | 3.46 | – |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 113% | 5.7% |
| Held by insiders | 2.6% | 31.4% |
| Insider net buying, 12 months | −$35.7M | – |
Go deeper
- LGND stock overview
- LGND income statement
- LGND valuation and score
- OGI stock overview
- OGI income statement
- OGI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.